What this covers
This Business Breakdowns conversation pairs host Zack with Julia, who walks through Argenx from both the science and the investing side. The science starts with autoimmune disease, which she describes as poorly understood and nearly as hard as the brain. Steroids and IVIG calm the immune system indiscriminately. IVIG can take over eight hours to infuse and carries risks including acute renal failure. Against that, she sets Argenx's approach of blocking the recycling of pathogenic autoantibodies so they clear out, with fewer off-target effects. The discussion also covers why llama antibodies are useful and why CIDP, where about 30% of patients end up in wheelchairs, is a case of unmet need.
The second half is about money and organization. Julia lays out the financing problem: drug development takes over a decade and billions of dollars, with an industry success rate near 10%. European investors are more risk averse, and Argenx got by on raises of no more than about $60 million. She then describes the anchor investor role played by Baillie Gifford, which put in over $200 million in the first round and followed with more, including a $1 billion raise completed the day before. She also covers OrbiMed's early push toward a platform strategy. She stresses that Argenx's core competence is antibody development, with disease biology coming from academic partners.
She puts the approval odds for Argenx's drugs at 60 to 70 percent, which is contestable. She names cultural dilution as the biggest risk once a commercial arm gains influence. She also argues that commercial buildout should begin in Phase II, and that execution teams matter more than the technology itself.
Argenx's edge is a llama-derived antibody platform that targets a specific recycling pathway, combined with academic partnerships and long-term investors, which Julia argues makes its drug approval odds and capital efficiency far better than typical biotech.
- Targeting the antibody recycling pathway removes pathogenic autoantibodies while sparing healthy ones, giving a mechanism-based and more specific treatment than steroids or IVIG
- Academic partnerships and patient-focused trial design lower risk, which Julia argues lifts approval probabilities from roughly 10% to 60-70%
- Long-term anchor investors funded the company through capital-intensive late-stage trials
Llama antibody platform with proprietary technology gives Argenx differentiation most antibody companies lack.
- Most antibody companies work with mice, a few experiment with sharks whose antibodies share commonality with llamas, and only a few companies, including Argenx, work with llamas.
“Most companies working with mice, and it's also quite a successful model, but there are experiments with sharks”
- Raw llama antibodies alone would not make a successful drug; Argenx layers a stack of proprietary technologies on top to make the molecules specific, safe, and convenient to administer.
“Argenx, of course, wouldn't be that successful if it just use pure llamas antibodies”
- Llamas have a differentiated type of antibody that allows things other animal models cannot do, and their antibodies are also similar to human antibodies, which matters for product quality.
“llamas actually have really differentiated type of antibodies that allow us to do new things that we couldn't do with any other types”
- Julia first found the llama-antibody story through Belgian company Ablynx, which was acquired by Sanofi shortly after she found it, and a few months later she was approached about Argenx.
“very shortly after I came across Ablynx, it got acquired by Sanofi”
- Using animal-derived antibodies to make therapies is not science fiction; the field was pioneered about four decades ago by companies such as Genentech, and most companies use mice.
“what we've been doing it for like four decades or even longer. So this is a field of antibodies that's been pioneered by companies like Genentech”
Autoimmune pipeline and approved drug point to very large, eventually highly profitable revenue potential.
- Adding the autoimmune diseases Argenx targets could bring the addressable population to over a million patients, with one disease alone having about 60,000 patients in Europe and a similar number in the US.
“the 60,000 patients in Europe is the same number. So when you start adding all those diseases together, you can easily get to over the million.”
- Given the strength of the underlying biology and negotiated pricing, Argenx's drug could become one of the best-selling drugs in history.
“you can easily see how it can become one of the best-selling drug in history”
- Once the remaining programs beyond the first four are included, Argenx's revenue potential could exceed $20 billion, a level only a few drugs ever reach.
“So therefore, you can see how it can get to more than $20 billion and there are only a few drugs that actually deliver that.”
- Argenx has roughly 15 to 16 visible autoimmune programs in the pipeline, and because its underlying biology applies broadly, it could expand by another 10, 20, or 30 diseases.
“around 15, 16, which are kind of more visible to us, which is in the pipeline”
- Until a drug reaches market, biotech revenue depends on partnership milestones, but commercialization diversifies revenue and lets a biotech become a sustainable business.
“until you have a drug on the market, you truly depend on milestones from your partnerships”
- Argenx's first approved drug generated about $400 million in its first year of launch and is growing strongly, supporting a projection of $7 to $8 billion in revenue from the first four programs within five to seven years.
“So therefore, you can see how it can get to more than $20 billion and there are only a few drugs that actually deliver that.”
- Argenx could become one of the highest-quality businesses in the industry, and its profitability should look more attractive than probably the best pharmaceutical companies because of superior capital efficiency.
“this company could skew risk-reward in such a way that it's also profoundly changes the economics of the business”
- Commercialized drug businesses have operating margins that vary widely across the industry, from roughly 30 to 40 percent for companies like Novo Nordisk down to the mid-20s for others.
“Novo Nordisk have operating margins in the range of -- from 30% to 40%. And then you can have those lower ones, more like in the mid-something 20s.”
- Investors model the visible advanced programs but invest on the invisible part of the pipeline, since more drugs will come, so valuation depends partly on pipeline expectations beyond current assets.
“we are modeling most what you can see, but still, we invest on the basis of the invisible part”
- Argenx may remain cash-sufficient over the next five years yet still burn significant cash, and may not show profits for three to five years, because it is choosing to keep investing in R&D given the opportunity size.
“We might not see any green numbers over the next three, five years, but this is certainly a very, very good business.”
Long-term investors and academic partnerships keep Argenx independent, flexible, and able to survive repeated funding rounds.
- Building collaborative relationships with academia requires a non-protective company culture that shares data and gives researchers freedom to experiment, which is why it is hard for others to copy.
“If the company behaves in a very protective way, if they don't share all the data, ... then that relationship will never work”
- Argenx is not primarily a biology company; its disease biology comes from academic research while the company's core competence is antibody development.
“What is really different about Argenx is that they're not a biology company. Actually, the entire biology know-how comes from academia.”
- When a company realizes it is platform-based rather than one-asset, it can pursue multiple drugs and remain independent instead of selling a single asset to large pharma.
“when they actually realize they don't need to be one asset company, but actually, they are platform-based, and they can think about multiple drugs”
- A US-based long-term investor, OrbiMed, joined early, providing capital and aligning the company toward a long-term platform strategy rather than a one-asset sale, which changed the company's strategy and independence.
“a U.S.-based investor and introduced, first gave more capital, but also aligned the interest with the company with a more long-term ambition”
- Argenx's collaborative project teams are so integrated that an outsider cannot tell which members are from the company and which are from academia.
“you wouldn't tell who is actually from the company and who is external from academia”
- As biotech companies advance to late-stage trials, capital needs rise sharply because recruiting many patients is far more expensive, so underfunded firms face a critical crossroads.
“as you move to the late-stage trials, they're much more expensive as you recruit more patients”
- Biotech startups in Europe face particularly difficult funding because European investors are more risk averse than US investors, and Argenx survived for years on raises of no more than about $60 million.
“the European investors tend to be even more risk averse than, for example, investors in the U.S.”
- Drug development takes more than a decade and billions of dollars, with an industry-wide success rate of around 10%, which makes biotech very hard to finance.
“it could take more than a decade to develop a drug and also takes billions of dollars, and success rate for the industry around 10%”
- Baillie Gifford made an anchor investment of more than $200 million in Argenx's first round, bought directly rather than in the secondary market, and then followed with three more rounds, including a $1 billion raise completed the previous day.
“the first round we've done, we invested more than $200 million in the company”
- The history of biotech is closely tied to the capital cycle, and Argenx's advantage lies in attracting long-term investors who will support the company through progress without forcing it to sacrifice its pipeline.
“the history of the biotech is really very much connected to the capital cycle”
- Baillie Gifford spent at least a year understanding Argenx's technology, management, alignment, and ambition before deciding to invest.
“we spent at least a year really trying to understand the technology, the management, how aligned we are”
- Large pharma partnerships are typically transactional and milestone-driven with little flexibility, while academic groups find Argenx's collaboration far more exploratory and open.
“in the case of large pharma, it's much more transactional. It's very much driven by milestones.”
- Argenx's first target came from an academic institute where researchers spent decades understanding disease biology, and the company's strategy is to find top specialist groups, learn from them, and partner to develop drugs.
“the first target of the company, it came from academic institute where actually researchers spend decades really studying the biology”
- Baillie Gifford tries to understand complex science by building long-term relationships with top academics and scientists in niche areas, sharing perspective and learning over time, rather than hiring every expert.
“we cannot hire all the brilliant minds. Certain areas are very niche areas. So our approach is really to build relationship also with academia”
- Companies should proactively build a shareholder base of long-term holders, because survival depends on attracting investors who will support the business over the long term.
“how you proactively build your shareholder base to ensure the survival of your business”
- Argenx's valuation is driven by future pipeline value and long-term investor support, not only by near-term revenue, and it is tied to an approach that remains independent.
“we invest on the basis of the invisible part”
- Long-term shareholders who back a company's multi-year ambition help it avoid selling its key asset early, which preserves the company's independence and the value its progress would otherwise be sacrificed for.
“the ability to attract long-term investors who are interested to supporting the company over the long term and making sure that whatever progress they made is not going to be sacrificed.”
Targeted pathogenic antibody recycling blockade and patient-focused design give Argenx a clear safety edge.
- Autoimmune diseases follow the same mechanism as allergies: the immune system mistakes healthy human cells for invaders and attacks them, as in type 1 diabetes where insulin-producing pancreatic cells are destroyed.
“Instead of pollen, immune system actually attacks healthy tissue, healthy cells of human body.”
- Argenx's drugs target the biological pathway that recycles pathogenic autoantibodies; blocking that recycling lets the harmful antibodies leave the system, so there is nothing left to attack healthy cells.
“they target a certain pathway in biology, which is responsible for recycling those pathogenic antibodies”
- Because healthy antibodies also need recycling, Argenx's drug must be precise: overdoing the blockade could cause infections, but the company has managed to block only pathogenic recycling and keep immune function intact.
“they target a certain pathway in biology, which is responsible for recycling those pathogenic antibodies”
- Early data from competitor drugs on the same target show a large safety gap versus Argenx's drug, which Julia argues is a key differentiator.
“when you compare their drug that goes exactly for the same target to Argenx's and there is a massive difference. More importantly, it's on the safety”
- Many drugs treat one condition while damaging another through off-target interactions, so side effects make patients refuse treatments, and Argenx prioritizes minimizing off-target effects.
“Very often, we take drugs and it treats one thing and then it damages another one.”
- Most companies run trials to meet regulatory requirements only, while Argenx also collected broader data on patient experience and life impact.
“Most of the companies run clinical trials with data points to get to the approval”
- Argenx's first-generation drug was intravenous, requiring a roughly one-hour hospital infusion, while the second-generation subcutaneous injection changes the treatment experience for patients.
“the first generation of that drug was based on intravenous treatment... But the second generation of the drug is subcutaneous.”
- Argenx's investment team asks whether a company's evidence shows real care for patients, because purely economic motives can look similar on the surface, and Julia believes patient-focused companies generate better investment returns.
“one of the questions in our research framework we have, what is the evidence that the company cares about patient”
Patient-first strategy and early commercial build-out determine approval odds, launch strength, and revenue risk.
- Argenx collected patient-reported experience data beyond regulatory requirements, which helped demonstrate real-world value to payers and contributed to a favorable price negotiation.
“they also collected additional type of data that captured actually the patients experienced more broadly”
- The probability of approval for Argenx's pipeline drugs is around 60 to 70 percent rather than the industry's 10 percent, because the company understands the biology it targets and the patient difference it makes.
“they are not 10%, they are look more like 60%, 70%, which is a very different proposition”
- Engaging patient groups early gave doctors understanding of the drug before launch, which helped produce one of the best commercial launches in biotech history.
“because they also engage with the patient groups early on in the process, the doctors already had understanding of the drug”
- Argenx's competitive strength is a patient-first strategy covering efficacy, safety, and convenience, which Julia argues is the company's main differentiator and leads to higher investment returns.
“the entire strategy was aligned around making a difference for a patient. And we strongly believe when you can truly do that, if you make a difference, then that would lead to investment returns.”
- Investors are watching whether Argenx's highly de-risked first drug approach repeats in other pipeline drugs, since a second promising readout suggests the platform may generalize across diseases and partnerships in oncology.
“Can the first drug, which is already highly derisked, can that type of approach being replicated to somewhere else in the pipeline?”
- Biotech companies should begin building commercial organization, sales force, and physician education during Phase II rather than waiting for Phase III results, because waiting until Phase III makes launches poorly executed.
“they invested already in Phase II in the commercial organization, when normally company is waiting for Phase III results”
- Argenx stood out on execution, and management and company culture play an incredibly important role in Baillie Gifford's investment process, with patient focus as a core research question.
“management and the company's culture plays incredible role. One it's a major ingredient in our investment process.”
- The biggest risk to Argenx is cultural dilution as it becomes a commercial organization, because a powerful commercial arm can drive decisions by revenue opportunity rather than science, damaging R&D decisions.
“the biggest risk is a cultural dilution, especially when you become the commercial organization”
- The key lesson of investing in biotech is that people who execute on the technology matter more than the technology itself, and identifying unique execution groups takes screening many companies.
“it's not the cool technology that makes it. It's all about people.”
- Using patient counts and negotiated U.S. pricing, Julia estimates the first four programs could generate $7-8 billion within five to seven years, and the full pipeline could exceed $20 billion, a level few drugs reach.
“you can see how it can become $7 billion, $8 billion opportunity within next five, seven years... So therefore, you can see how it can get to more than $20 billion”
Existing autoimmune treatments are crude and burdensome, while Argenx's therapy is quick and convenient.
- CIDP is a progressive autoimmune disease in which the immune system attacks nerve cells, and about 30% of patients end up in a wheelchair, with no proper treatment currently available.
“it's a progressive disease and at certain stage, patients actually losing ability to move and 30% of patients end in a wheelchair”
- Current autoimmune treatments such as steroids and immunoglobulins pacify the immune system in an undifferentiated way, and the mechanism of IVIG is not well understood even though it works.
“the current way of approaching it is pretty much like when we throw steroids because they just pacify the immune system in a very undifferentiated way”
- Intravenous immunoglobulin takes more than eight hours to infuse in hospital and can cause flu-like symptoms, vomiting, rashes, and a risk of acute renal failure, making current autoimmune treatment rather barbaric.
“it takes more than eight hours to infuse the therapy in the hospital. And after that, patients might experience flu-like symptoms.”
- Argenx's therapy can be administered in about 30 seconds, and patients will eventually self-administer it without doctors or nurses, which is a major convenience advance over existing hospital infusions.
“it can be administered just within 30 seconds and eventually patients will be able to do it themselves”
Autoimmune biology is poorly understood, and competition mainly comes from shifting standard of care.
- For autoimmune diseases with high unmet need, the main competition is not other companies but changing standard of care and doctors' mindsets, though later competitors such as UCB and J&J will target the same biology.
“it's more competition of changing the standard of care and changing the mindset of the doctors”
- Autoimmune disease biology is very poorly understood, which is why treatments have not been developed to be specific, and the immune system's complexity makes autoimmunity nearly as hard as the brain.
“The whole area of autoimmune diseases is very poorly understood”
Genomics and data science are opening previously intractable diseases beyond cancer.
- Cancer is the most well-funded and researched area, which is why it is most advanced, and other diseases are now catching up thanks to genomics, large-scale sequencing, and data science.
“cancer is probably the most well-funded and researched area”
- The biggest unknown competitive threat is a disruptive alternative biology pathway that could be more powerful, requiring investors to stay open-minded as science advances.
“anything disruptive that could happen in terms of the technologies because there might be another biology pathway that could be even more powerful”
- Argenx could potentially pursue larger diseases such as multiple sclerosis, and the company is at the beginning of building out its technology across many diseases.
“they can really also potentially go for bigger diseases, multiple sclerosis is one of those”
- Advances in genome sequencing at scale and data science are profoundly shifting understanding of disease biology, letting researchers tackle diseases that were previously intractable.
“this is connected to genomics, our ability to sequence genomes at scale, and also data science”
- The llama-antibody research connection between two Belgian companies traces back to students who discovered the antibodies at a Belgian research institute, which became a hub for llama antibody study.
“it was done in the Belgium Research Institute, and this became a hub for llamas and studying the property of their antibodies.”
- Cancer has the most funding and research, and autoimmune disease is poorly understood, with complexity second only to the brain, which is why Argenx's understanding of the biology is a rare asset.
“The whole area of autoimmune diseases is very poorly understood, and that's why so far, we haven't been able to actually develop a treatment which is very specific”